Table 1 The promising targets and its inhibitors of lipid metabolism in T. gondii
From: Lipid metabolism: the potential targets for toxoplasmosis treatment
Pathway | Target | Inhibitor |
|---|---|---|
Fatty acid | Â | Â |
 FAS I | FAS |  |
PKS | Â | |
 FAS II | ACP |  |
PDH | Â | |
FabI | Triclosan | |
 FAE | ELO-A |  |
ELO-B | Â | |
ELO-C | Â | |
ATS | Â | |
Glycerol phospholipids | Â | Â |
 CDP-DG pool | CDS |  |
DGKs | R59022 | |
LIPIN | Â | |
PAP | Propranolol | |
CDPK7 | Â | |
PTS | Â | |
PIS | Â | |
 CDP-ethanolamine | EK |  |
ECT | Â | |
EPT | Â | |
PSD | Â | |
 CDP-choline | CK |  |
ASH | JCP341, JCP342, JCP343, JCP348, and JCP383 | |
 Scavenge | P4-ATPase |  |
Lem1 | Â | |
Degradation system | PC phospholipase | D609 |
PL2 | Atglistatin | |
Sphingomyelin | SPT | L-cycloserine |
SLS | Â | |
Cholesterol | GRA7 | Â |
LCAT | Â | |
ABCG | Â | |
Rab5 | Â | |
ACAT | DuP 128 and CI 976 | |
NPC | Â | |
P-gp | Â | |
Triglyceride | DGAT | T863 |